| General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes RR Wakaskar Journal of drug targeting 26 (4), 311-318, 2018 | 165 | 2018 |
| Passive and Active Targeting in Tumor Microenvironment RR Wakaskar International Journal of Drug Development and Research 9 (2), 37-41, 2017 | 88 | 2017 |
| Promising effects of nanomedicine in cancer drug delivery RR Wakaskar Journal of drug targeting 26 (4), 319-324, 2018 | 72 | 2018 |
| Sildenafil sublingual spray formulations T Potta, K Amancha, W Giron, N Yan, V Goskonda, ON Singh, H Redman, ... US Patent 10,111,833, 2018 | 69* | 2018 |
| Polymeric micelles and their properties RR Wakaskar J. Nanomed. Nanotechnol 8 (2), 10.4172, 2017 | 47 | 2017 |
| Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean … RR Wakaskar, SPR Bathena, SB Tallapaka, VV Ambardekar, N Gautam, ... Pharmaceutical research 32, 1028-1044, 2015 | 40 | 2015 |
| The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG (5K) VV Ambardekar, RR Wakaskar, B Sharma, J Bowman, W Vayaboury, ... Biomaterials 34 (20), 4839-4848, 2013 | 34 | 2013 |
| Polymeric Micelles for Drug Delivery RR Wakaskar International Journal of Drug Development and Research 9 (3), 2, 2017 | 31 | 2017 |
| Brief overview of nanoparticulate therapy in cancer RR Wakaskar Journal of drug targeting 26 (2), 123-126, 2018 | 29 | 2018 |
| Types of Nanocarriers - Formulation Methods and Applications RR Wakaskar Journal of Bioequivalence and Bioavailability 9 (2), 10000e77, 2017 | 29 | 2017 |
| Challenges pertaining to adverse effects of drugs RR Wakaskar International Journal of Drug Development and Research 9 (3), 1-2, 2017 | 21 | 2017 |
| Cancer Therapy with Drug Delivery Systems RR Wakaskar Journal of Pharmacogenomics and Pharmacoproteomics 8 (1), 100e1578, 2017 | 18 | 2017 |
| Role of nanoparticles in drug delivery encompassing cancer therapeutics RR Wakaskar Int. J. Drug Dev. Res 93, 3-4, 2017 | 8 | 2017 |
| Sublingual opioid formulations containing naloxone N Shan, RR Wakaskar, EA Baldwin, AB Schlinkert, M Wu, N Yan US Patent 10,265,309, 2019 | 6* | 2019 |
| Utilization of nanoparticulate therapy in cancer targeting E Narayanan, R Wakaskar Cogent Medicine 5 (1), 1504504, 2018 | 6 | 2018 |
| Effect of peripheral shell cross-linking on the efficacy of a hydrophobic vascular disrupting agent physically loaded in core-shell polymeric micelles RR Wakaskar | 6 | 2015 |
| Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL (30)-PEG (5K) in primary murine syngeneic breast … VV Ambardekar, RR Wakaskar, Z Ye, SM Curran, TR McGuire, ... International journal of pharmaceutics 543 (1-2), 130-138, 2018 | 4 | 2018 |
| Cancer Therapy with the Aid of Nanotherapeutics RR Wakaskar Journal of Biomolecular Research and Therapeutics 6 (2), 2, 2017 | 4 | 2017 |
| A Phase 1, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults With … J Chen, S Chilampalli, G DeCastro, E Narayanan, RR Wakaskar, GJ Atiee Journal of Allergy and Clinical Immunology 143 (2), AB144, 2019 | 3 | 2019 |
| Methods of stabilizing epinephrine E Narayanan, R Wakaskar, C Chilampalli, T Potta, VR Goskonda US Patent 11,077,075, 2021 | 2 | 2021 |
